IO102-IO103: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •3 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (3 countries listed)
Risk Assessment
IO102-IO103 has not been approved by any regulatory authority. The phase 3 trial narrowly missed statistical significance. The FDA recommended against filing a BLA based on the current dataset. IO Biotech is evaluating strategic options for additional development.
The pivotal phase 3 IOB-013 trial showed an 8.4-month PFS improvement but did not meet the pre-specified hazard ratio threshold of 0.65. While clinically meaningful, the regulatory pathway forward requires additional data or analysis.
IO102-IO103 must be combined with checkpoint inhibitors, which carry inherent risks of immune-related adverse events including potentially severe colitis, hepatitis, pneumonitis, and endocrine dysfunction. Standard checkpoint inhibitor monitoring and management apply.
⚠️Important Warnings
- •Investigational biologic: IO102-IO103 is not approved for any indication. Use only within authorized clinical trials.
- •Phase 3 statistical limitation: The pivotal trial showed clinically meaningful PFS improvement but did not meet the pre-specified threshold for statistical significance.
- •Checkpoint inhibitor required: IO102-IO103 must be combined with checkpoint inhibitor therapy. All risks of checkpoint inhibitor therapy apply.
- •Immunosuppression caution: Systemic immunosuppressive therapy may impair vaccine-induced immune responses and should be minimized during treatment.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Investigational | FDA Breakthrough Therapy Designation granted December 2020 for IO102-IO103 plus anti-PD-1 in unresectable/metastatic melanoma. However, following a pre-BLA meeting in September 2025, the FDA recommended against filing based on the current phase 3 dataset alone. IO Biotech is evaluating next steps. |
| European Union | Investigational | Not EMA-approved. No European marketing authorization application has been filed. Clinical trials have been conducted at EU sites. |
| International | Investigational | Not approved in any jurisdiction. Clinical trial sites span the US, Europe, and other regions. IO Biotech (Copenhagen, Denmark) is the sponsor. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 10+ community reports
View community protocolsCritical Safety Information#
IO102-IO103 (Cylembio) is an investigational dual-peptide cancer vaccine developed by IO Biotech. It has not been approved by any regulatory authority. While FDA Breakthrough Therapy Designation was granted in 2020, the phase 3 trial narrowly missed its statistical significance threshold, and the FDA has recommended against filing a BLA on the current dataset alone. All safety information is derived from clinical trials.
Investigational Status Risk#
The regulatory uncertainty for IO102-IO103 represents the primary risk context:
- The phase 3 IOB-013/KN-D18 trial showed an 8.4-month improvement in median PFS (19.4 vs 11.0 months) but did not meet the pre-specified HR threshold of 0.65
- Following a pre-BLA meeting (September 2025), the FDA recommended against filing a BLA
- IO Biotech is evaluating strategic options, which may include additional trials, post-hoc analyses, or partnership
- The path to regulatory approval remains uncertain
- Patients have access only through clinical trial enrollment
Phase 3 Statistical Considerations#
The phase 3 result merits careful interpretation:
What the Data Show#
- 8.4-month improvement in median PFS (19.4 vs 11.0 months)
- PFS improvement consistent across all predefined subgroups
- Particularly pronounced benefit in PD-L1-negative patients (16.6 vs 3.0 months)
- No increase in immune-mediated adverse events
- ORR numerically higher in the combination arm (44.8% vs 41.2%)
Statistical Limitations#
- The pre-specified HR threshold of 0.65 was not met
- This threshold was aggressive for a combination added to an active comparator
- The overall result is considered clinically meaningful but statistically insufficient for regulatory filing
- Additional data (longer follow-up, additional trial, or subgroup-enriched design) may be needed
Checkpoint Inhibitor Risks#
IO102-IO103 requires combination with checkpoint inhibitors, which carry well-established risks:
Immune-Related Adverse Events#
| Event | Incidence with Anti-PD-1 | Potential Severity | Management |
|---|---|---|---|
| Colitis | 5-15% | Can be life-threatening | Corticosteroids, infliximab |
| Hepatitis | 5-10% | Grade 3-4 possible | Corticosteroids, mycophenolate |
| Pneumonitis | 2-5% | Can be fatal | Corticosteroids, hold therapy |
| Thyroiditis | 10-20% | Usually manageable | Hormone replacement |
| Dermatitis | 15-25% | Rarely severe | Topical/systemic corticosteroids |
| Myocarditis | <1% | Can be fatal | ICU, corticosteroids |
The key finding is that IO102-IO103 does not increase these risks beyond what is expected with checkpoint inhibitor monotherapy.
Checkpoint Inhibitor Contraindications#
Standard checkpoint inhibitor contraindications apply:
- Active autoimmune disease requiring immunosuppression
- Prior organ transplant (risk of rejection)
- Active severe infection
- ECOG performance status >2
Vaccine-Specific Safety Considerations#
Montanide ISA-51 Adjuvant#
- The water-in-oil emulsion can cause persistent injection site nodules or granulomas
- Rare hypersensitivity reactions to mineral oil-based adjuvants have been reported
- Some cancer vaccine trials have observed injection site ulceration with Montanide-based formulations
Immunosuppression Interaction#
- Systemic corticosteroids above 10 mg prednisone equivalent may impair vaccine efficacy
- This creates a tension if immune-related AEs from the checkpoint inhibitor require corticosteroid treatment
- The clinical impact of concurrent corticosteroid use on IO102-IO103 efficacy is not well characterized
Regulatory and Legal Status#
IO102-IO103 is not approved for use in any country.
| Jurisdiction | Status | Key Details |
|---|---|---|
| United States (FDA) | Investigational | BTD granted 2020; BLA not recommended; strategic review |
| European Union (EMA) | Investigational | No MAA filed |
| International | Investigational | Global trials conducted |
IO Biotech, Inc. is a Nasdaq-listed (IOBT) company headquartered in Copenhagen, Denmark.
Risk Mitigation#
For Patients Considering Clinical Trials#
- Understand that IO102-IO103 is investigational and the phase 3 trial did not meet its primary statistical endpoint
- Discuss checkpoint inhibitor risks with the oncology team
- Ensure awareness of potential immune-related adverse events and monitoring requirements
- Report any new symptoms promptly during treatment
- Understand that treatment access may depend on clinical trial availability
For Investigators#
- Follow standard checkpoint inhibitor monitoring and management guidelines
- Monitor injection sites for persistent reactions
- Minimize systemic immunosuppression when possible to preserve vaccine efficacy
- Consider PD-L1 status in patient selection, given the pronounced subgroup benefit
- Collect correlative immune biomarkers per protocol
Related Reading#
Frequently Asked Questions About IO102-IO103
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.